Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Bolt Biotherapeutics, Inc.

Market Cap 8.51M 7.39M 6.81M 6.38M 11.92M 815M 12.17M 81.23M 31.45M 393M 31.96M 31.27M 1.37B P/E Ratio 2026 *
-0.02x
P/E Ratio 2027 * -0.02x
Enterprise Value 8.51M 7.39M 6.81M 6.38M 11.92M 815M 12.17M 81.23M 31.45M 393M 31.96M 31.27M 1.37B EV / Sales 2026 *
5.64x
EV / Sales 2027 * 2.43x
Free-Float
92.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Bolt Biotherapeutics, Inc.

1 day+3.27%
1 week-3.89%
Current month-12.86%
1 month-2.66%
3 months+10.77%
6 months-21.93%
Current year-16.33%
1 week 4.3
Extreme 4.3
4.95
1 month 4.25
Extreme 4.2501
5.7
Current year 3.91
Extreme 3.91
7.2
1 year 3.91
Extreme 3.91
7.2
3 years 3.91
Extreme 3.91
34.2
5 years 3.91
Extreme 3.91
385.7
10 years 3.91
Extreme 3.91
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 14/05/2024
Chief Executive Officer 54 14/05/2024
Chief Operating Officer 61 14/05/2024
Director TitleAgeSince
Director/Board Member 64 30/11/2020
Director/Board Member 54 14/05/2024
Chairman 55 03/09/2024
Date Insider Type Main position Quantity % Market Cap.
01-27Buy

Controller/Auditor

8,125 0.4233%
01-27Free

Chief Operating Officer

10,000 0.5210%
01-27Buy

Chief Executive Officer

20,125 1.0485%
Change 5-day change 1-year change 3-year change Capi.($)
+3.27%-3.89%-29.94%-85.97% 8.51M
+1.65%+6.42%+53.16%+109.62% 54.82B
+0.03%-1.80%+49.57%+43.94% 43.27B
+3.06%-1.52%-16.34%-19.64% 21.79B
+6.15%-8.30%-1.81%+393.38% 19.92B
+0.81%-8.38%+12.77%-33.24% 15.67B
+0.53%+2.08%+8.89%-40.13% 15.26B
+2.12%+1.35%+28.41%+178.68% 13.22B
-5.27%+3.89%+90.88%+208.02% 11.58B
-1.74%-1.05%+12.88% - 11.94B
Average +1.06%-0.95%+20.85%+83.85% 20.75B
Weighted average by Cap. +1.20%+1.16%+31.73%+96.93%

Financials

2026 *2027 *
Net sales 1.51M 1.31M 1.21M 1.13M 2.11M 144M 2.16M 14.4M 5.57M 69.63M 5.66M 5.54M 242M 3.5M 3.04M 2.8M 2.62M 4.9M 335M 5M 33.4M 12.93M 162M 13.14M 12.86M 562M
Net income -44.52M -38.64M -35.61M -33.37M -62.35M -4.26B -63.65M -425M -164M -2.05B -167M -164M -7.14B -47.5M -41.22M -38M -35.6M -66.52M -4.55B -67.91M -453M -175M -2.19B -178M -174M -7.62B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
11/06/26 4.575 $ +3.27% 82,029
10/06/26 4.430 $ -4.11% 11,476
09/06/26 4.620 $ -2.12% 4,843
08/06/26 4.720 $ +3.51% 6,700
05/06/26 4.560 $ -4.20% 10,991
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.430USD
Average target price
41.00USD
Spread / Average Target
+825.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!